Melinda Knight, MD
Urology · Wakefield, RINPI 1134176076
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Medtronic at 42.9% of the total. Reporting peaked in 2023 at $2,278 and has fallen 84.5% since, to $354 in 2025.
Across 93 payments — averaging $59.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$2K
- Intuitive Surgical$648
- Axonics, Inc.$158
- Sumitomo Pharma America, Inc.$132
- Biotissue Holdings Inc.$128
- plus $534 from 14 others
What the payments were for
- Travel & lodging$2,74950%
- Food & beverage$2,74950%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $2,358 |
| Boston Scientific | 15 | $1,540 |
| Intuitive Surgical | 11 | $648 |
| Axonics, Inc. | 13 | $158 |
| Sumitomo Pharma America, Inc. | 1 | $132 |
| Biotissue Holdings Inc. | 2 | $128 |
| Procept Biorobotics Corporation | 1 | $121 |
| Progenics Pharmaceuticals, Inc. | 1 | $64 |
| Pfizer | 3 | $57 |
| Rochester Medical Corporation | 2 | $51 |
| Antares Pharma, Inc. | 2 | $38 |
| Coloplast | 2 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $27 |
| Davol Inc. | 1 | $27 |
| Blue Earth Diagnostics | 1 | $27 |
| Ambu Inc. | 2 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,671
- GENERAL BPH$1,096
- Da Vinci Surgical System$427
- Moses 550 DFL$140
- ORGOVYX$132
- AQUABEAM SYSTEM$121
How this compares
$5,498 in reported general payments places this provider in the 70th percentile of 55 urology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 270 | $146,785 |
| GemtesaVibegron | 127 | $72,126 |
| EstringEstradiol | 57 | $30,478 |
| Estradiol | 339 | $19,739 |
| Mirabegron ErMirabegron | 26 | $12,666 |
| Methenamine Hippurate | 82 | $4,973 |
| Oxybutynin Chloride ErOxybutynin Chloride | 217 | $3,130 |
| Solifenacin Succinate | 72 | $2,870 |
| Trospium Chloride ErTrospium Chloride | 31 | $2,324 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 73 | $1,581 |
| Trospium Chloride | 39 | $1,422 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $965 |
| Cephalexin | 178 | $820 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $809 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 18 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $33 | $146,785270 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $132 | $72,126127 claims |
| PfizerEstring | $57 | $30,47857 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 urology providers in Rhode Island.
Other urology in Wakefield
- Katelyn JohnsonWakefield$886
- Dicken KoProvidence$158K
- Gyan PareekProvidence$83K
- Joseph RenzulliProvidence$81K
- Simone ThavaseelanProvidence$16K
- Boris GershmanProvidence$13K
- Mark LeoWest Warwick$13K
- Janice Santos CortesProvidence$12K
- Joseph CambioWest Warwick$11K
- Dragan GolijaninProvidence$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.